Inhibition of neutrophil activity in cardiac surgery with cardiopulmonary bypass: a novel strategy with the leukocyte inhibition module.
Recently, we showed that the arterial in-line application of the leukocyte inhibition module (LIM) within the heart-lung machine limits overshooting leukocyte activity and cardiac tissue damage. Moreover, significantly better cardiac function was found in an experimental animal model when LIM was used. In the meantime, the first promising clinical data exist. LIM has to be regarded as an essential tool in extracorporeal circulation, in the future, to improve postoperative clinical outcome and to reduce costs. This review summarizes the biological background of LIM and the current experience obtained in experimental models and clinical studies.
Moreno
José Bitu
JB
Department of Vascular Surgery, Medical Faculty of Marília (FAMEMA), Sao Paulo, Brazil.
Margraf
Stefan
S
Schuller
Alina M
AM
Simon
A
A
Moritz
A
A
Scholz
M
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D020099:Coated Materials, Biocompatible; D005112:Extracorporeal Circulation; D005374:Filtration / Q000295:instrumentation; D006801:Humans; D007937:Leukapheresis / Q000295:instrumentation*; D007962:Leukocytes; D018375:Neutrophil Activation / Q000187:drug effects; D019014:fas Receptor / Q000276:immunology
D000911:Antibodies, Monoclonal; D020099:Coated Materials, Biocompatible; D019014:fas Receptor